BLUE EARTH DIAGNOSTICS TEAM
Jonathan Allis was the founding CEO of Blue Earth Diagnostics. Prior to this role, Jonathan was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcare’s PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc, Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany.
Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford.
Jonathan is married with three children.
David Gauden is the President Research and Development and Chief Scientific Officer at Blue Earth Diagnostics. Prior to joining Blue Earth he was Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the portfolio mix, licensing, product development and strategic marketing activities for a range of developmental PET drugs. Now with more than 20 years in the medical imaging industry, David has deep expertise across the business spectrum. He held roles of increasing seniority within supply chain, project management, IP licensing and clinical development. David has an undergraduate degree from the University of Warwick and a doctorate in Biochemistry from the University of Oxford.
Terri Wilson is the President of Blue Earth Diagnostics Inc., and a member of its Board of Directors. She joined Blue Earth Diagnostics in 2016. Terri is passionate about how policy can impact access to both diagnostic imaging and therapy for patients fighting cancer.
Terri has more than 20 years of experience in the nuclear medicine industry. Prior to joining Blue Earth Diagnostics, she held leadership positions of increasing responsibility in sales, marketing, and market access at organizations such as PETNET Solutions, Siemens, Cardinal Health, and MITA (Medical Imaging & Technology Alliance). She began her career as a nuclear medicine technologist. She continues to serve as the vice-chair of the MITA PET Group and co-chair of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Value Initiative Industry Alliance.
Terri holds a B.S. in Nuclear Medicine from the University of Missouri and an MBA with a focus on Pharmaceutical Marketing from Saint Joseph’s University in Philadelphia, PA.
Jonathan Fitzpatrick is the Vice President Human Resources at Blue Earth Diagnostics. Jonathan has over 20 years of experience in Human Resources, the majority of which has been spent with the Bracco Group which he joined in 2002. In those 20 years of careers he held various roles, leading HR for the Canadian operations of Bracco for 7 years. He holds a Bachelor of Science in Industrial Relations from the University of Montreal and is a Chartered Professional in Human Resources.
Andrea Scampoli is the Chief Financial Officer at Blue Earth Diagnostics. Andrea has many years’ experience in Pharmaceuticals and Diagnostics, and joined the Bracco Group in 2013. He has held several senior finance roles in different businesses and companies, DHL Express, PepsiCo and GE Industrial. He has a degree in Business Administration.
Peter Gardiner is the Chief Medical Officer at Blue Earth Diagnostics. He has more than 30 years’ experience in clinical development and medical affairs gained from roles at BG Medicine, Bristol-Myers Squibb Medical Imaging, DuPont Pharmaceuticals, Gensia and GD Searle. Most recently, he was Vice President, Medical Affairs for Blue Earth Diagnostics in the United States. Peter qualified in medicine from the University of Leeds and is Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine. He is also a scientific advisor on medical imaging to global biopharmaceutical services company PAREXEL.
Chelsea is an intellectual property (IP) lawyer with commercial, corporate, litigation and governance experience. Dual-qualified as an English Solicitor and Australian Legal Practitioner, Chelsea started her career as a Nuclear Medicine Technologist having obtained an undergraduate degree in Medical Radiations before studying law. She worked for several years at international law firms Bird & Bird LLP and Herbert Smith Freehills in London, Melbourne and The Hague advising clients in the life sciences sector. Most recently Chelsea was Associate Director at LifeArc supporting translational research and funding activity. Chelsea completed postgraduate IP studies at the University of Oxford in 2012 and is a member of the BioIndustry Association IP Advisory Committee. She is also an Independent Trustee at the Institute of Physics and Engineering in Medicine.